Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome

Thromb Res. 2012 Apr;129(4):499-501. doi: 10.1016/j.thromres.2011.06.019. Epub 2011 Jul 12.

Abstract

Introduction: In patients with metabolic syndrome (MetS), activity of the fibrinolytic system is generally surmised to be decreased through increased plasminogen activator inhibitor-1 (PAI-1) generation. However, there have been no detailed reports describing whether the clot lysis activity is more dominant than increased clot formation activity for production of the thrombotic state in MetS.

Methods: The global thrombosis test (GTT) is a novel method designed to test both clot formation and clot lysis activities under physiological conditions by using non-anticoagulated blood samples in vitro. We used the GTT to examine the thrombotic or thrombolytic states in males with MetS.

Results: Lysis time, which reflects spontaneous clot lysis activity, was significantly longer in MetS subjects (median, 1494s; range, 865-3596s; n=30) than in control subjects (median 1246s; range, 667-2239s; n=53). There was no significant difference between the two groups in occlusion time, which reflects platelet function. The mean level of PAI-1 was significantly higher in MetS subjects than in controls (mean ± SE, 8.7 ± 1.1 and 5.0 ± 0.5 ng/mL, respectively). PAI-1 level and lysis time were significantly correlated (r=0.400, P<0.01).

Conclusion: These results suggest that male patients with MetS are more likely than controls to experience a thrombotic state through decreased fibrinolytic activity due to increased PAI-1 generation, and that the GTT is useful for evaluating fibrinolytic activity in vitro.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Comorbidity
  • Humans
  • Japan / epidemiology
  • Male
  • Metabolic Syndrome / diagnosis*
  • Metabolic Syndrome / epidemiology*
  • Platelet Function Tests / methods*
  • Platelet Function Tests / statistics & numerical data*
  • Prevalence
  • Reproducibility of Results
  • Risk Assessment
  • Risk Factors
  • Sensitivity and Specificity
  • Thrombosis / diagnosis*
  • Thrombosis / epidemiology*